Incident Gallstones During Somatostatin Analog Treatment are Associated with Acute Biliary Complications Especially After Discontinuation

What Was Tested

The paper reports a study of Somatostatin, published as a randomized controlled trial.

The aim of this study was to investigate the incidence of gallstones on imaging and related complications in unbiased trial data.

Why It Was Studied

Gallstones are a known adverse effect of somatostatin analogs, but the exact incidence and clinical implications are unknown.

ClinicalTrials.gov ( https://clinicaltrials.gov ); NCT01616927.

Who Took Part

The study group was 305 patients.

Data from the DIPAK 1 trial, in which 305 polycystic kidney disease patients were randomized to standard of care (SoC) or lanreotide for 120 weeks, were used.

Magnetic resonance imaging (MRI) was performed at baseline and end of treatment and was assessed for the presence, number, and size of gallstones.

How the Study Was Run

The researchers set it up as a randomized study.

Random assignment meant chance, not the researchers, decided who got Somatostatin and who got the comparison, which limits bias.

A time span of 120 weeks appears in the methods.

For all patients who had gallstones at the end of the trial, the researchers obtained follow-up after the trial.

What Was Measured

Topics PubMed links to this paper include Gallstones and Somatostatin.

What This Means in Plain Language

The paper is a randomized study of Somatostatin in 305 patients over 120 weeks.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2021 (Drugs in R&D), a journal based in New Zealand.

More context: the Somatostatin compound page, all human trials.